Target Price | CHF302.35 |
Price | CHF265.50 |
Potential | 13.88% |
Number of Estimates | 20 |
20 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF302.35. This is 13.88% higher than the current stock price. The highest price target is CHF454.00 71.00% , the lowest is CHF220.00 17.14% . | |
A rating was issued by 25 analysts: 10 Analysts recommend Roche to buy, 11 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 13.88% . Most analysts recommend the Roche stock at Hold. |
20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.5b . This is 4.94% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.0b 10.74% , the lowest is CHF60.7b 0.41% .
This results in the following potential growth metrics:
2024 | CHF60.5b | 3.03% |
---|---|---|
2025 | CHF63.5b | 4.94% |
2026 | CHF66.2b | 4.25% |
2027 | CHF68.8b | 3.98% |
2028 | CHF71.9b | 4.51% |
2029 | CHF75.0b | 4.30% |
16 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.0b . This is 22.40% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF26.2b 28.37% , the lowest is CHF21.9b 7.16% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF20.4b | 8.34% |
---|---|---|
2025 | CHF25.0b | 22.40% |
2026 | CHF26.3b | 4.98% |
2027 | CHF27.2b | 3.52% |
2028 | CHF29.5b | 8.51% |
2029 | CHF29.2b | 0.94% |
2024 | 33.78% | 5.15% |
---|---|---|
2025 | 39.40% | 16.62% |
2026 | 39.68% | 0.71% |
2027 | 39.50% | 0.45% |
2028 | 41.02% | 3.85% |
2029 | 38.96% | 5.02% |
13 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF14.5b . This is 74.81% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF16.8b 102.72% , the lowest is CHF10.4b 25.79% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF8.3b | 28.01% |
---|---|---|
2025 | CHF14.5b | 74.81% |
2026 | CHF15.5b | 7.37% |
2027 | CHF16.5b | 6.09% |
2028 | CHF17.0b | 3.23% |
2029 | CHF18.9b | 10.96% |
2024 | 13.68% | 30.13% |
---|---|---|
2025 | 22.79% | 66.57% |
2026 | 23.47% | 2.98% |
2027 | 23.95% | 2.05% |
2028 | 23.66% | 1.21% |
2029 | 25.17% | 6.38% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 10.32 | 18.19 |
27.83% | 76.26% | |
P/E | 14.60 | |
EV/Sales | 3.58 |
13 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF18.19 . This is 76.26% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF21.10 104.46% , the lowest is CHF13.09 26.84% .
This results in the following potential growth metrics and future valuations:
2024 | CHF10.32 | 27.83% |
---|---|---|
2025 | CHF18.19 | 76.26% |
2026 | CHF19.53 | 7.37% |
2027 | CHF20.72 | 6.09% |
2028 | CHF21.39 | 3.23% |
2029 | CHF23.74 | 10.99% |
Current | 25.73 | 59.68% |
---|---|---|
2025 | 14.60 | 43.25% |
2026 | 13.59 | 6.92% |
2027 | 12.81 | 5.74% |
2028 | 12.41 | 3.12% |
2029 | 11.19 | 9.83% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.58 and an P/S ratio of 3.31 .
This results in the following potential growth metrics and future valuations:
Current | 3.76 | 6.52% |
---|---|---|
2025 | 3.58 | 4.74% |
2026 | 3.44 | 4.08% |
2027 | 3.30 | 3.83% |
2028 | 3.16 | 4.31% |
2029 | 3.03 | 4.12% |
Current | 3.47 | 8.01% |
---|---|---|
2025 | 3.31 | 4.71% |
2026 | 3.17 | 4.08% |
2027 | 3.05 | 3.83% |
2028 | 2.92 | 4.31% |
2029 | 2.80 | 4.12% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Mar 21 2025 |
JEFFERIES |
Hold
➜
Hold
|
Unchanged | Mar 11 2025 |
STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Mar 02 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Feb 02 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Mar 21 2025 |
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Mar 11 2025 |
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Mar 02 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Feb 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.